Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3149MR)

This product GTTS-WQ3149MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3149MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14555MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ10372MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ11174MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ6921MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ432MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ11856MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ15048MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW